» Articles » PMID: 26074443

Cirrhotic Cardiomyopathy in the Pre- and Post-liver Transplantation Phase

Overview
Journal J Cardiol
Publisher Elsevier
Date 2015 Jun 16
PMID 26074443
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with advanced liver cirrhosis may develop a clinical syndrome characterized by a blunted contractile responsiveness to stress and/or altered diastolic relaxation, called "cirrhotic cardiomyopathy." This syndrome, which is initially asymptomatic, is often misdiagnosed due to the presence of symptoms that characterize other disorders present in patients with advanced liver cirrhosis, such as exercise intolerance, fatigue, and dyspnea. Stress and other conditions such as liver transplantation and transjugular intrahepatic portosystemic shunt (TIPS) may unmask this syndrome. Liver transplantation in this group of patients results in a clinical improvement and can be a cure for the cardiomyopathy. However, post-transplant prognosis depends on the identification of cirrhotics with cardiomyopathy in the pre-transplant phase; an early diagnosis of cirrhotic cardiomyopathy in the pre-transplant phase may avoid an acute onset or worsening of cardiac failure after liver transplantation. Since a preserved left ventricular ejection fraction may mask the presence of cirrhotic cardiomyopathy, the use of newer noninvasive diagnostic techniques (i.e. tissue Doppler, myocardial strain) is necessary to identify cirrhotics with this syndrome, in the pre-transplant phase. A pre-transplant treatment of heart failure in cirrhotics with cardiomyopathy improves the quality of life in this phase and reduces the complications during and immediately after liver transplantation. Since specific therapies for cirrhotic cardiomyopathy are lacking, due to the absence of a clear understanding of the pathophysiology of the cardiomyopathy, further research in this field is required.

Citing Articles

H2FPEF Scores Are Increased in Patients with NASH Cirrhosis and Are Associated with Post-liver Transplant Heart Failure.

Koch D, Rockey D, Litwin S, Tedford R Dig Dis Sci. 2024; 69(8):3061-3068.

PMID: 38782854 PMC: 11341588. DOI: 10.1007/s10620-024-08438-1.


Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting.

Nadim M, Kellum J, Forni L, Francoz C, Asrani S, Ostermann M J Hepatol. 2024; 81(1):163-183.

PMID: 38527522 PMC: 11193657. DOI: 10.1016/j.jhep.2024.03.031.


Evaluation of Electrocardiogram Parameters and Heart Rate Variability During Blood Pressure Elevation by Phenylephrine in Cirrhotic Rats.

Ketabchi F, Khoram M, Dehghanian A Cardiovasc Toxicol. 2024; 24(3):321-334.

PMID: 38409566 DOI: 10.1007/s12012-024-09839-4.


The Contemporary Role of Speckle Tracking Echocardiography in Cirrhotic Cardiomyopathy.

Dimitroglou Y, Aggeli C, Alexopoulou A, Tsartsalis D, Patsourakos D, Koukos M Life (Basel). 2024; 14(2).

PMID: 38398688 PMC: 10890501. DOI: 10.3390/life14020179.


Hepatocardiorenal syndrome in liver cirrhosis: Recognition of a new entity?.

Wu H, Rakisheva A, Ponnusamy A, Chinnadurai R World J Gastroenterol. 2024; 30(2):128-136.

PMID: 38312119 PMC: 10835518. DOI: 10.3748/wjg.v30.i2.128.